日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.

发现 BMS-986365,一种首创的双重雄激素受体配体导向降解剂和拮抗剂,用于治疗晚期前列腺癌。

Nayak Surendra, Norris John D, Ammirante Massimo, Rychak Emily, Wardell Suzanne E, Liao Debbie, Toyama Brandon, Kandimalla Raju, Christoforou Andy, Tsuji Toshiya, Liu Ken, Tran Minerva, Meiring Joseph, Reiss Samantha, Piccotti Joseph R, Baughman Joshua M, Fontanillo Celia, Khater Marwa, Mortensen Deborah S, Cathers Brian, Bence Neil, Pierce Daniel W, Plantevin-Krenitsky Veronique, Rathkopf Dana, Hansen Joshua D, Hamann Lawrence G, Narla Rama Krishna, Arora Vivek K, McDonnell Donald P, Rolfe Mark, Xu Shuichan

Recent advances in glutarimide chemistry for cereblon-mediated targeted protein degradation: developments in synthesis and diversification

谷氨酰胺化学在 cereblon 介导的靶向蛋白降解中的最新进展:合成和多样化方面的进展

Ba, Xiaochu; Dehghany, Mahzad; Mortensen, Deborah S; Holmberg-Douglas, Natalie

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

双重 mTORC1/mTORC2 抑制作为结核病不同病理小鼠模型中宿主导向的治疗靶点

Tasneen, Rokeya; Mortensen, Deborah S; Converse, Paul J; Urbanowski, Michael E; Upton, Anna; Fotouhi, Nader; Nuermberger, Eric; Hawryluk, Natalie

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

一项 I 期剂量递增研究,旨在评估双重 mTORC1/mTORC2 激酶抑制剂 CC-223 在晚期实体瘤或多发性骨髓瘤患者中的安全性、耐受性、药代动力学和初步疗效。

Bendell, Johanna C; Kelley, Robin K; Shih, Kent C; Grabowsky, Jennifer A; Bergsland, Emily; Jones, Suzanne; Martin, Thomas; Infante, Jeffrey R; Mischel, Paul S; Matsutani, Tomoo; Xu, Shuichan; Wong, Lilly; Liu, Yong; Wu, Xiaoling; Mortensen, Deborah S; Chopra, Rajesh; Hege, Kristen; Munster, Pamela N

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

mTOR 激酶抑制剂 CC214-1 和 CC214-2 优先阻断 EGFRvIII 激活的胶质母细胞瘤的生长

Gini Beatrice, Zanca Ciro, Guo Deliang, Matsutani Tomoo, Masui Kenta, Ikegami Shiro, Yang Huijun, Nathanson David, Villa Genaro R, Shackelford David, Zhu Shaojun, Tanaka Kazuhiro, Babic Ivan, Akhavan David, Lin Kelly, Assuncao Alvaro, Gu Yuchao, Bonetti Bruno, Mortensen Deborah S, Xu Shuichan, Raymon Heather K, Cavenee Webster K, Furnari Frank B, James C David, Kroemer Guido, Heath James R, Hege Kristen, Chopra Rajesh, Cloughesy Timothy F, Mischel Paul S